Dendritic Cells and their Potential Therapeutic Role in Haematological Malignancy

References

• Ben-Efraim, S. (1999) "One hundred years of cancer immuno-therapy: a critical appraisal", Tumor Biol. 20, 1–24.
   PubMed Web of Science ®Google Scholar
• Burnet, F.M. (1970) "The concept of immunological surveillance", Prog. Exp. Tumor Res. 13, 1–27 (Karger, Basel/Munchen/ New York).
   Google Scholar
• Banchereau, J. and Steinman, R.M. (1998) "Dendritic cells and the control of immunity", Nature 392, 245–252.
   PubMed Web of Science ®Google Scholar
• Lanzavecchia, A. (1999) "Dendritic cell maturation and generation of immune responses", Haematologica 84, 23–25.
   PubMedGoogle Scholar
• Lanzavecchia, A. and Sallusto, F. (2001) "Regulation of T cell immunity by dendritic cells", Cell 106, 263–266.
   PubMed Web of Science ®Google Scholar
• Romani, N., Reider, D., Heuer, M., Ebner, S., Kampgen, E., Eibl, B., Niederwieser, D. and Schuler, G. (1996) "Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability", J. ImmunoL Methods 196, 137–151.
   PubMed Web of Science ®Google Scholar
• Morse, MA., Thou, Li., Tedder, T.F., Lyerly, H.K. and Smith, C. (1997) "Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4 and tumor necrosis factor-a for use in cancer immunotherapy", Ann. Surg. 226, 6–16.
   PubMed Web of Science ®Google Scholar
• Young, J.W. (1999) "Dendritic cells: expansion and differentiation with hematopoietic growth factors", Curr. Opin. HematoL 6, 135–144.
   PubMedGoogle Scholar
• Van Pel, A., van der Bruggen, P., Coulie, P.G., Brichard, V.G., Lethe, B., van den Eynde, B., Uyttenhove, C., Renauld, J.C. and Boon, T. (1995) "Genes coding for tumor antigens recognised by cytolytic T lymphocytes", ImmunoL Rev. 145, 229–250.
   PubMed Web of Science ®Google Scholar
• Avignan, D. (1999) "Dendritic cells: development, function and potential use for cancer immunotherapy", Blood Rev. 13, 51–64.
   PubMed Web of Science ®Google Scholar
• Reid, C.D.L. (1998) "The biology and clinical applications of dendritic cells", Transfus. Med. 8, 77–86.
   PubMed Web of Science ®Google Scholar
• Pawelec, G., Rees, R.C., Kiessling, R., Madrigal, A., Dodi, A., Baxevanis, C., Gambacorti-Passerini, C., Masucci, G. and Zeuthen, J. (1999) "Cells and cytokines in immunotherapy and gene therapy of cancer", Crit. Rev. Oncog. 10, 83–127.
   PubMed Web of Science ®Google Scholar
• Timerman, J.M. and Levy, R. (1999) "Dendritic cell vaccines for cancer immunotherapy", Annu. Rev. Med. 50, 507–529.
   PubMed Web of Science ®Google Scholar
• Colaco, C.A.L.S. (1999) "Why are dendritic cells central to cancer immunotherapy?", MoL Med. Today 5, 14–17.
   PubMedGoogle Scholar
• Reid, C.D.L. (2001) "Dendritic cells and immunotherapy for malignant disease", Br. J. HeamatoL 112, 874–888.
   PubMed Web of Science ®Google Scholar
• Trojan, A., Shultze, J.L., Witzens, M., Vonderheide, R.H., Laden°, M., Donovan, J.W. and Gribben, J.G. (2000) "Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell maliganancies", Nat. Med. 6, 667–672.
   PubMed Web of Science ®Google Scholar
• Hang, S., Witzens, M., Krackhardt, A.M., Trojan, A., Barrett, P., Broderick, R., Zauls, J. and Gribben, J.G. (2001) "Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues", Blood 98, 2999–3005.
   PubMed Web of Science ®Google Scholar
• Kwak, L.W., Campbell, M.J., Czerwinski, D.K., Hart, S., Miller, R.A. and Levy, R. (1992) "Induction of immune responses in patients with B-cell lymphoma against the surface immuno-globulin idiotype expressed by their tumours", N. Engl. J. Med. 327, 1209–1215.
   PubMed Web of Science ®Google Scholar
• Nelson, E.L., Xiobin, L., Hsu, F.J., Kwak, L.W., Levy, R., Clayberger, C. and Krensky, A.M. (1996) "Tumour-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkins lymphoma", Blood 88, 580–589. poj Hsu, F.J., Caspar, C.B., Czerwinski, D., Kwak, L.W., Liles, T.M., Syrengelas, A., Taidi-Laskowski, B. and Levy, R. (1997) "Tumour-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long term results of a clinical trial", Blood 89, 3129–3135.
   Google Scholar
• Bendandi, M., Gocke, C.D., Kobrin, C.B., Benko, F.A., Stemas, L.A., Pennington, R., Watson, T.M., Reynolds, C.W., Gause, B.L., Duffey, P.L., Jaffe, E.S., Creekmore, S.P., Longo, D.L. and Kwak, L.W. (1999) "Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma", Nat. Med. 5, 1171–1177.
   PubMed Web of Science ®Google Scholar
• Hsu, F.J., Benike, C., Fagnoni, F., Liles, T.M., Czerwinski, D., Taidi, B., Engleman, E.G. and Levy, R. (1996) "Vaccination of [5] patients with B-cell lymphomas using autologous antigen-pulsed dendritic cells", Nat. Med. 2, 52–58.
   PubMed Web of Science ®Google Scholar
• Osterroth, F., Garbe, A., Fisch, P. and Veelken, H. (2000) "Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells", Blood 95, 1342–1349.
   PubMed Web of Science ®Google Scholar
• Timmerman, J.M., Czerwinski, D.K., Davis, TA., Hsu, F.J., Bethke, C., Hao, Z.M., Taidi, B., Rajapaksa, R., Caspar, C.B., Okada, C.Y., Hao, Z.M., Taisi, TM., Engleman, E.G. and Levy, R. (2002) "Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients", Blood 99, 1517–1526.
   PubMed Web of Science ®Google Scholar
• Kwak, LW., Taub, D.D., Duffey, EL., Bensinger, W.I., Bryant, EM., Reynolds, C.W. and Longo, D.L. (1995) "Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor", Lancet 345, 1016–1020.
   PubMed Web of Science ®Google Scholar
• Bergenbrant, S., Yi, Q., Osterborg, A., Bjorkholm, M., Osby, E., Mellstedt, H., lefvert, A.K. and Holm, G. (1996) "Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients", Br J. Haematol. 92, 840–846.
   PubMed Web of Science ®Google Scholar
• Osterberg, A., Yi, Q., Henriksson, L., Qing, Yi., Henriksson, L., Fagerberg, J., Bergenbrant, S., Jeddi-Tehrani, M., Ruden, U., Lefvert, A.-K., Holm, G. and Mellstedt, H. (1998) "Idiotype immunisation combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses", Blood 91, 2459–2466.
   PubMed Web of Science ®Google Scholar
• Pfeiffer, S., Gooding, R.P., Apperley, J.F., Goldschmidt, H. and Samson, D. (1997) "Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and function-ally identical to those produced from healthy donors", Br J. Haematol. 98, 973–982.
   PubMed Web of Science ®Google Scholar
• Wen, Y.J., Ling, M., Bailey-Wood, R. and Lim, H. (1998) "Idiotype protein-pulsed adherent peripheral blood mononuclear cell derived dendritic cells prime immune system in multiple myeloma", Clin. Cancer Res. 4, 957-962. poj Dabadghao, S., Bergenbrant, S., Anton, D., He, W., Holm, G. and Yi, Q. (1998) "Anti-idiotype T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells", Br J. Haematol. 100, 647–654.
   Web of Science ®Google Scholar
• Cull, G., Durrant, L., Stainer, C., Haynes, A. and Russell, N. (1999) "Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma", Br J. Haematol. 107, 648–655.
   PubMed Web of Science ®Google Scholar
• Lim, S.H. and Bailey-Wood, R. (1999) "Idiotype protein-pulsed dendritic cell vaccination in multiple myeloma", Int. J. Cancer 83, 215–222.
   PubMed Web of Science ®Google Scholar
• Titzer, S., Christensen, 0., Manzke, 0., Tesch, H. and Wolf, J. (2000) "Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects", Br J. Haematol. 108, 805–816.
   PubMed Web of Science ®Google Scholar
• Ratta, M., Curti, A., Fogli, M., Pantucci, M., Viscomi, G., Tazzari, P., Fagnoni, F., Vescovini, R., Sansoni, P., Tura, S. and Lemoli, R.M. (2000) "Efficient presentation of tumor idiotype to autologous cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+) monocytes in multiple myeloma patients", Exp. Haematol. 28, 93 1— 940.
   Google Scholar
• Liso, A., Stockerl-Goldstein, K.E., Auffemann-Gretzinger, S., Bnike, C.J., Reichardt, V, van Beckhoven, A., Rajapaksa, R., Engleman, E.G., Blume, KG. and Levy, R. (2000) "Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma", Biol. Blood Marrow Transplant. 6, 621–627.
   PubMed Web of Science ®Google Scholar
• Wen, Y.J., Barlogie, B. and Yi, Q. (2001) "Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells", Blood 97, 1750–1755.
   PubMed Web of Science ®Google Scholar
• Butch, A.W., Kelly, K.A. and Munshi, N.C. (2001) "Dendritic cells derived from multiple myeloma patients efficiently internalise different classes of myeloma protein", Exp. Haematol. 29, 85–92.
   PubMed Web of Science ®Google Scholar
• Wen, Y.J., Min, R., Tricot, G., Barlogie, B. and Yi, Q. (2002) "Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy", Blood 99, 3280–3285.
   PubMed Web of Science ®Google Scholar
• Yi, Q., Desikan, R., Barlogie, B. and Munshi, N. (2002) "Optimising dendritic cell-based immunotherapy in multiple myeloma", Br J. Haematol. 117, 297–305.
   PubMed Web of Science ®Google Scholar
• Dhodapkar, UV, Krasovsky, J. and Olson, K. (2002) "T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells", Proc. Nall Acad. Sci. USA 99, 13009–13013.
   PubMed Web of Science ®Google Scholar
• Choudhury, A., Gajewski, J.L., Liang, J.C., Popat, U., Claxton, D.F., Kliche, K.-0., Andreeff, M. and Champlin, RE. (1999) "Use of leukaemic DCs for the generation of anti-leukaemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukaemia", Blood 89, 1133–1142.
   Web of Science ®Google Scholar
• Eibl, B., Ebner, S., Duba, C., Bock, G., Romani, N., Erdel, M., Gachter, A., Niederwiser, D. and Schuler, G. (1997) "Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response", Genes Chromosomes Cancer 20, 215–223.
   PubMed Web of Science ®Google Scholar
• Coleman, S., Throp, D., Fisher, J., Bailey-Wood, R. and Lim, S.H. (1997) "Cytokine enhancement of immunogenicity in chronic myeloid leukemia", Leukemia 11, 2055–2059.
   PubMed Web of Science ®Google Scholar
• Lim, S.H., Coleman, S. and Bailey-Wood, R. (1998) "In vitro cytokine-primed leukaemia cells induce in vivo T cell respon-siveness in chronic myeloid leukaemia", Bone Marrow Transplant. 22, 1185–1190.
   PubMed Web of Science ®Google Scholar
• Nieda, M., Nicol, A., Kikuchi, A., Kashiwase, K., Taylor, K., Suzuki, K., Tadokoro, K. and Juli, T. (1998) "Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia", Blood 91, 977–983.
   PubMed Web of Science ®Google Scholar
• Wang, C., Al-Omar, H.M., Radvanyi, L., Banerjee, A., Bouman, D., Squire, J. and Messner, HA. (1999) "Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by 1FN-alpha", Exp. Hematol. 27, 1176–1184.
   PubMed Web of Science ®Google Scholar
• Engels, EH., Koski, G.K., Bedrosian, I., Xu, S., Luger, S., Nowell, P.C., Cohen, RA. and Czerniecki, B.J. (1999) "Calcium signalling induces acquisition of dendritic cell characteristics in chronic myelogenous leukaemia myeloid progenitor cells", Proc. Natl Acad. Sci. USA 96, 10332–10337.
   PubMed Web of Science ®Google Scholar
• Osman, Y, Takahashi, M., Zhend, Z., Koike, T., Toba, K., Lui, A., Furakawa, T., Aoki, S. and Aizawa, Y. (1999) "Generation of bcr/abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr/abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients", Leukemia 13, 166–174.
   PubMed Web of Science ®Google Scholar
• Fuji i, A., Shimizu, K., Fujimoto, K., Kiyokawa, T., Shimomura, T., Tanaguchi, 0., Kinoshita, M. and Kawano, F. (1999) "Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation", Jpn J. Cancer Res. 90, 1117–1129.
   PubMedGoogle Scholar
• Zheng, C., Pisa, P., Stromberg, 0., Blennow, E. and Hansson, M. (2000) "Generation of dendritic cells from peripheral blood of patients at different stages of chronic myeloid leukemia", Med. Oncol. 17, 270–278.
   Web of Science ®Google Scholar
• Muller, L., Provenzani, C., Faul, C. and Pawelec, G. (2001) "Recognition of chronic myelogenous leukaemia cells by autologous T lymphocytes primed in vitro against the patient's DCs", Br J. Haematol. 112, 740–748.
   PubMed Web of Science ®Google Scholar
• Muller, L., Provenzani, C. and Pawelec, G. (2001) "Generation of chronic myelogenous leukaemia-specific T cells in cytokine-modified autologous mixed lymphocyte/tumour cell cultures", J. Immunother 24, 482–492.
   PubMed Web of Science ®Google Scholar
• Sun, J.Y., Krouse, R.S., Forman, S.J., Senitzer, D., Sniecinski, I., Chatterjee, S. and Wong, K.K., Jr. (2002) "Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro", Cancer Res. 62, 3175–3183.
   PubMed Web of Science ®Google Scholar
• Farace, F., Orlanducci, F., Dietrich, P.Y., Gaudin, C., Angevin, E., Courtier, M.H., Bayle, C., Hercend, T. and Triebel, F. (1994) "T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions", J. Immunol. 153, 4281–4290.
   PubMed Web of Science ®Google Scholar
• Rezvany, M.R., Jeddi-Tehrani, M., Rabbani, H., Lewin, N., Avila-Carino, J., Osterborg, A., Wigzell, H. and Mellstedt, H. (2000) "Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia", Br. J. Haematol. 111, 608–617.
   PubMed Web of Science ®Google Scholar
• Goddard, R.V., Prentice, AG., Copplestone, J.A. and Kaminski, E. (2001) "Generation in vitro of B-cells chronic lymphocytic leukaemia-proliferative and specific HLA class-II restricted cytotoxic T cell responses using autologous DCs pulsed with tumour cell lysate", Clin. Exp. Immunol. 125, 16–28.
   Web of Science ®Google Scholar
• Vuillier, F., Maloum, K., Thomas, E.K., Jouanne, C., Dighiero, G. and Scott-Algara, D. (2001) "Functional monocyte-derived dendritic cells can be generated in chronic lymphocytic leukaemia", Br J. Haematol. 115, 831–844.
   PubMed Web of Science ®Google Scholar
• Rezvany, MR., Jeddi-Tehrani, M., Biberfeld, P., Soderlund, J., Mellstedt, H., Osterborg, A. and Rabbani, H. (2001) "Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern", Br J. Haematol. 115, 263–271.
   PubMed Web of Science ®Google Scholar
• Goddard, R.V., Prentice, AG., Copplestone, J.A. and Kaminski, ER. (2003) "in vitro dendritic cell-induced T cell responses to B-cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids", Clin. Exp. Immunol. 131, 82–89.
   PubMed Web of Science ®Google Scholar
• Vuillier, F., Maloum, K., Thomas, E.K., Magnac, C., Dumas, G., Payelle-Brogard, B., Oppezo, P., Dighero, G. and Scott-Algara, D. (2003) "Idiotype-pulsed dendritic cells are able to induce anti-tumoral cytotoxic DC8 cells in chronic lymphocytic leukaemia", Br J. Haematol., In press.
   Google Scholar
• Tanaka, Y., Takahashi, T., Nieda, M., Masuda, S., Kashiwase, K., Ogawa, S., Chiba, S., Juji, T. and Hirai, H. (2000) "Generation of HLA-DRB1*1501-restricted p190 minor bcr-abl (ela2)-specific CD4+ T lymphocytes", Br. J. Haematol. 109, 435–437.
   PubMed Web of Science ®Google Scholar
• Pospisilova, D., Borovickova, J., Polouckova, A., Spisek, R., Hrusak, 0., Stary, J. and Bartunkova, J. (2002) "Generation of functional dendritic cells for potential use in the treatment of acute lymphoblastic leukaemia", Cancer Immunol. Immunother 51, 72–78.
   PubMed Web of Science ®Google Scholar
• Choudhury, A., Liang, J.C., Thomas, E.K., Flores-Romo, L., Xie, Q.S., Agusala, K., Sutaria, S., Sinha, I., Champlin, R.E. and Claxton, D.F. (1999) "Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses", Blood 93, 780–786.
   PubMed Web of Science ®Google Scholar
• Brouwer, R.E., van der Hoorn, M., Kluin-Nelemans, H.C., van Zelderen-Bhola, S., Willemze, R. and Falkenburg, J.H. (2000) "The generation of dendritic-like cells with increased allostimu-latory function from acute myeloid leukemia cells of various FAB subclasses", Hum. Immunol. 61, 565–574.
   PubMed Web of Science ®Google Scholar
• Woiciechowsky, A., Regn, S., Kolb, H.J. and Roskrow, M. (2001) "Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia", Leukemia 15, 245–255.
   Google Scholar
• Harrison, B.D., Adams, J.A., Briggs, M., Brereton, M.L. and Liu Ym, J.A. (2001) "Stimulation of autologous proliferative and cytotoxic T-cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukaemia", Blood 97, 2764–2771.
   Google Scholar
• Nieda, M., Nicol, A., Koezuka, Y, Kikuchi, A., Lapteva, N., Tanaka, Y., Tokunaga, K., Suzuki, K., Kayagaki, N., Yagita, H., Hirai, H. and Juji, T. (2001) "TRAIL expression by activated human CD4(+)V alpha24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells", Blood 97, 2067–2074.
   PubMed Web of Science ®Google Scholar
• Brugger, W., Schneider, A., Schammann, T., Dill, P., Grunebach, F., Buhring, H.J., Kanz, L. and Brossart, P. (2001) "Dendritic cell-based vaccines in patients with hematological malignancies", Ann. N.Y. Acad. Sci. 938, 359–363.
   PubMed Web of Science ®Google Scholar
• Galea-Lauri, J., Darling, D., Mufti, G., Harrison, P. and Farzaneh, F. (2002) "Eliciting cytotoxic T lymphocytes against acute myeloid leukaemia-derived antigens: evaluation of dendritic cell-leukaemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination", Cancer Immunol. Immunother. 51, 299–310. poj Spisek, R., Chevallier, P., Morineau, N., Milpied, N., Avet-Loiseau, H., Harousseau, J.L., Meflah, K. and Gregoire, M. (2002) "Induction of leukaemic-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin", Cancer Res. 62, 2861–2868.
   Google Scholar
• Rigolin, G.M., Howard, J., Buggins, A., Sneddon, C., Castoldi, G., Hirst, W.J.R. and Mufti, G.J. (1999) "Phenotypic and functional characteristics of monocyte-derived dendritic cells from patients with myelodysplastic syndromes", Br J. Haematol. 107, 844–850.
   PubMed Web of Science ®Google Scholar
• Osman, Y, Takahashi, M., Zheng, Z., Toba, K., Liu, A., Furukawa, T., Narita, M., Aizawa, Y., Koldke, T. and Shibata, A. (1999) "Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileuke-mia immunotherapy", J. Exp. Clin. Cancer Res. 18, 485–492.
   PubMed Web of Science ®Google Scholar
• Ohminami, H., Yasukawa, M. and Fujita, S. (2000) "HLA class I-restricted lysis of leukemia cells by a CD8(+ ) cytotoxic T-lymphocyte clone specific for WT1 peptide", Blood 95, 286–293.
   PubMed Web of Science ®Google Scholar
• Knights, A.J., Zaniou, A., Rees, R.C., Pawelec, G. and Muller (2002) "Prediction of an HLA-DR-binding peptide from Wilms' tumour 1 protein and demonstration of in vitro inununogenicity of WT1 (124–138)-pulsed dendritic cells generated according to an optimised protocol", Cancer Immunol. Immunother 51,271–281.
   Google Scholar
• Montagna, D., Maccario, R., Locatelli, F., Rosti, V, Yang, Y., Farness, P., Morena, A., Comoli, P., Montini, E. and Vitiello, A. (2001) "Ex vivo priming for long term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy", Blood 98, 3359–3366.
   PubMed Web of Science ®Google Scholar
• Fujii, S., Shimizu, K., Fujimoto, K., Kiyokawa, T., Tsukamoto, A., Sanada, I. and Kawano, F. (2001) "Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells", Leuk. Lymphoma 42, 357–369.
   PubMed Web of Science ®Google Scholar
• Krackhardt, AM., Harig, S., Witzens, M., Broderick, R., Barrett, P. and Gribben, J.G. (2002) "T-cell responses against chronic lymphocytic leukaemia cells: implications for immunotherapy", Blood 100, 167–173.
   PubMed Web of Science ®Google Scholar
• Gong, J., Chen, D., Kashiwaba, M. and Kufe, D. (1997) "Induction of antitumour activity by immunisation with fusions of dendritic and carcinoma cells", Nat. Med. 3, 558–561.
   PubMed Web of Science ®Google Scholar
• Gong, J., Chen, D., Kashiwaba, M., Li, Y, Chen, L., Takeuchi, H., Qu, H., Rowse, G.J., Gender, S.J. and Kufe, D. (1998) "Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunised with fusions of dendritic and carcinoma cells", Proc. Natl Acad. Sci. USA 95, 6279–6283.
   PubMed Web of Science ®Google Scholar
• Gong, J., Nikrui, N., Chen, D., Koido, S., Wu, Z., Tanaka, Y, Cannistra, S., Avignan, D. and Kufe, D. (2000) "Fusions of human ovarian carcinoma cells with autologous or allogeneic DCs induce antitumour immunity", J. Immunol. 165, 1705–1711.
   PubMed Web of Science ®Google Scholar
• Kikuchi, T., Akasaki, Y, Irie, M., Homma, S., Abe, T. and Ohno, T. (2001) "Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells", Cancer Immunol. Immunother. 50, 337–344.
   PubMed Web of Science ®Google Scholar
• Kugler, A., Stuhler, G., Walden, P., Zoller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Muller, C.A., Becker, V, Gross, A.J., Hemmerlein, B., Kanz, L., Muller, G.A. and Ringed, R.H. (2000) "Regression of human metastatic renal cell carcinoma after vaccination with tumour cell-dendritic cell hybrids", Nat. Med. 6, 332–336.
   PubMed Web of Science ®Google Scholar
• Hersey, P. (1999) "Impediments to successful immunotherapy", Phannacol. Ther. 81, 111–119.
   Web of Science ®Google Scholar
• Jonuleit, H., Schmitt, E., Steinbrink, K. and Enk, A.H. (2001) "Dendritic cells as a tool to induce anergic and regulatory T cells", Trends Immunol. 22, 394–400.
   PubMed Web of Science ®Google Scholar
• Gabrilovich, DI., Chen, H.L., Girgis, KR., Cunningham, H.T., Meny, G.M., Nadaf, S., Kavanaugh, D. and Carbone, D.P. (1996) "Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells", Nat. Med. 2, 1096–2003.
   PubMed Web of Science ®Google Scholar
• De Visser, K.E. and Kast, W.M. (1999) "Effects of TGF-I3 on the immune system: implications for cancer immunotherapy", Leukemia 13, 1188–1199.
   PubMed Web of Science ®Google Scholar
• Bright, J.J., Kerr, L.D. and Sriram, S. (1997) "TFG-13 inhibits IL-2 induced tyrosine phosphorylation and activation of JAK-1 and STAT 5 in T lymphocytes", J. Immunol. 159, 175–183.
   PubMed Web of Science ®Google Scholar
• Cook, G., Campbell, J.D., Boyd, KS., Carr, C.E. and Franklin, I.M. (1999) "Transforming growth factor 13 (TGF-13) from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes", J. Leukoc. Biol. 66, 981–988.
   PubMed Web of Science ®Google Scholar
• Campbell, J.D., Cook, G., Robertson, SE., Fraser, A., Boyd, KS., Gracie, J.A. and Franklin, I.M. (2001) "Suppression of
   Google Scholar
• IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumour-derived TGF beta is reversed by IL-15", J. Immunol. 167, 553–561. poj Brown, RD., Pope, B., Muray, A., Esdale, W., Sze, D.M., Gibson, J., Ho, P.J., Hart, D. and Joshua, D. (2001) "Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to upregulate CD80 (B7-1) expression after huCD5OLT stimulation because of inhibition by transforming growth factor-beta 1 and interleukin-10", Blood 98, 2992–2998.
   Google Scholar
• Steinbrink, K., Jonuleit, H., Muller, G., Schuler, G., Knop, J. and Enk, AR (1999) "Interleukin-10-treated dendritic cells induced a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumour cells", Blood 93, 1634–1642.
   PubMed Web of Science ®Google Scholar
• Chakraborty, A., Li, L, Chakraborty, N.G. and Mukherji, B. (2000) "Stimulatory and inhibitory differentiation of human myeloid dendritic cells", Clin. Immunol. 94, 88–98.
   PubMed Web of Science ®Google Scholar
• Rata, M., Fagnoni, F., Curti, A., Vescovini, R., Sansoni, P., Oliviero, B., Fogli, M., Ferri, E., Della Cuna, G.R., Tura, S., Baccarani, M. and Lemoli, R.M. (2002) "Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6", Blood 100, 230–237.
   PubMed Web of Science ®Google Scholar
• Hilkens, C.M.U., Kalinski, P., de Boer, M. and Kapsenberg, M.L. (1997) "Human dendritic cells require exogenous Interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Thl phenotype", Blood 90, 1920–1926.
   PubMed Web of Science ®Google Scholar
• Grohmann, U., Fioretti, MC., Bianchi, R., Belladonna, ML., Ayroldi, E., Surace, D., Silla, S. and Puccetti, P. (1998) "Dendritic cells, interleukin 12, and CD4+ lymphocytes in the initiation of class-I-restricted reactivity to a tumor/self peptide", Grit. Rev. Immunol. 18, 87–98.
   PubMed Web of Science ®Google Scholar
• Nagayama, H., Sato, K., Kawasaki, H., Enomoto, M., Morimoto, C., Tadokoro, K., Juji, T., Asano, S. and Takahashi, TA. (2000) "IL-12 responsiveness and expression of IL-12 receptor in human peripheral blood monocyte derived dendritic cells", J. Immunol. 165, 59–66.
   PubMed Web of Science ®Google Scholar
• Gong, J., Koido, S., Chen, D., Tanaka, Y., Huang, L., Avignan, D., Anderson, K., Ohno, T. and Kufe, D. (2002) "Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12", Blood 99, 2512–2517.
   PubMed Web of Science ®Google Scholar
• Scrivener, S., Kaminski, ER., Demaine, A. and Prentice, AG. (2001) "Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation", Br J. Haematol. 112, 959–964.
   PubMed Web of Science ®Google Scholar
• Roskrow, MA., Dilloo, D., Suzuki, N., Thong, W., Rooney, CM. and Brenner, M.K. (1999) "Autoimmune disease induced by dendritic cell immunization against leukemia", Leuk. Res. 23, 549–557.
   PubMed Web of Science ®Google Scholar
• Ludewig, B., Ochsenbein, AF., Odermatt, B., Paulin, D., Hengartner, H. and Zinkernagel, R.M. (2000) "Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease", J. Exp. Med. 191, 795–804.
   PubMed Web of Science ®Google Scholar